Download PDF
Augenheilkunde up2date 2019; 9(01): 9-15
DOI: 10.1055/a-0759-2432
Handlungspfade
Georg Thieme Verlag KG Stuttgart · New York

Verlaufskontrolle nach IVOM-Therapie bei diabetischem Makulaödem

Mohammad Saleh
,
Seleman Bedar
Further Information

Publication History

Publication Date:
20 February 2019 (online)

Also available at
    Permissions and Reprints All articles of this category

Ziel dieses Beitrages ist, dem Leser einen Leitfaden für eine strukturierte Untersuchung bei Patienten mit diabetischem Makulaödem bei der Kontrolle während oder nach der IVOM-Therapie zu geben. Ein Schwerpunkt liegt dabei auf der OCT-basierten Therapieentscheidung.
 

  • Literatur

  • 1 Wild PS, Pfeiffer N, Mirshahi A. et al. Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS One 2015; 10: e0139527 doi:10.1371/journal.pone.0139527
    CrossrefPubMedGoogle Scholar
  • 2 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806
    CrossrefPubMedGoogle Scholar
  • 3 Frank RN. Etiologic Mechanisms in Diabetic Retinopathy. Retina 2005; 2: 1241-1270 doi:10.1016/B978-0-323-02598-0.50072-0
    CrossrefGoogle Scholar
  • 4 Duker JS, Waheed NK, Goldmann DR. Handbook of retinal OCT: Optical Coherence Tomography. London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto: Elsevier Saunders; 2014
    Google Scholar
  • 5 Sarangi R, Silva PS, Aiello LP. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema. JAMA Ophthalmol 2014; 132: 1309-1316
    CrossrefPubMedGoogle Scholar
  • 6 Bolz M, Schmidt-Erfurth U, Deak G. et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009; 116: 914-920 doi:10.1016/j.ophtha.2008.12.039
    CrossrefPubMedGoogle Scholar
  • 7 Framme C, Schweizer P, Imesch M. et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2012; 53: 5814-5818 doi:10.1167/iovs.12-9950
    CrossrefPubMedGoogle Scholar
  • 8 Ota M, Nishijima K, Sakamoto A. et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology 2010; 117: 1996-2002
    CrossrefPubMedGoogle Scholar
  • 9 Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectraldomain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51: 5965-5969 doi:10.1167/iovs.10-5779
    CrossrefPubMedGoogle Scholar
  • 10 Coscas G, De Benedetto U. Coscas Fet al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229: 32-37
    CrossrefPubMedGoogle Scholar
  • 11 Uji A, Murakami T, Nishijima K. et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol 2012; 153: 710-717
    CrossrefPubMedGoogle Scholar
  • 12 Schreur V, Altay L, van Asten F. et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One 2018; 13: e0206482 doi:10.1371/journal.pone.0206482
    CrossrefPubMedGoogle Scholar
  • 13 Campos A, Campos EJ, do Carmo A. et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema. Eye Vis (Lond) 2018; DOI: 10.1186/s40662-018-0119-9.
    CrossrefPubMedGoogle Scholar
  • 14 Regatieri CV, Brannchini L, Carmody J. et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012; 32: 563-568
    CrossrefPubMedGoogle Scholar
  • 15 Manjunath V, Taha M, Fujimoto JG. et al. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol 2010; 150: 325-329.e1
    CrossrefPubMedGoogle Scholar
  • 16 DRCR.NET. Protocol I – Macular Laser Combined with Ranibizumab or Triamcinalone vs. Macular Laser Alone. Am J Ophthalmol 2016; 164: 57-68
    CrossrefPubMedGoogle Scholar
  • 17 DRCR.NET. Protocol T-Aflibercept, Bevacizumab or Ranibizumab for Diabetic Macular Edema. N Engl J Med 2015; 372: 1193
    CrossrefPubMedGoogle Scholar
  • 18 DRCR.NET. Protocol S – Panretinal Photocoagulation vs. lntravitreal Ranibizumab for Proliferative Diabetic Retinopathy. JAMA 2015; 314: 2137-2146
    CrossrefPubMedGoogle Scholar
  • 19 Nguyen QD, Brown DM, Marcus DM. et al. Ranibizumab for diabetic macular edema, results from 2 phase III randomized trials: RISE und RIDE. J Ophtha 2012; 119: 789-801
    Google Scholar
  • 20 Heier JS, Korobelnik JF, Brown DM. et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology 2016; 123: 2376-2385 doi:10.1016/j.ophtha.2016.07.032
    CrossrefPubMedGoogle Scholar
  • 21 Rajendram R, Fraser-Bell S, Kaines A. et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data. Arch Ophthalmol 2012; 130: 972-979
    PubMedGoogle Scholar
  • 22 Pacella F, Romano MR, Turchetti P. et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 2016; 9: 1427-1432
    PubMedGoogle Scholar
  • 23 Nentwich MM, Lemmen KD, Ulbig MW. Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulaopathie. Z Prakt Augenheilkd 2010; 31: 491-499
    Google Scholar